Data on effect of Sacubitril/valsartan on cardiac Remodelling in diabetic Cardiomyopathy rats

Data Brief. 2021 Mar 18:35:106963. doi: 10.1016/j.dib.2021.106963. eCollection 2021 Apr.

Abstract

Diabetic cardiomyopathy (DCM) is one of the most important causes of death in patients with diabetic mellitus. The effect of sacubitril/valsartan (Sac/Val) on cardiac remodeling in DCM remains unclear. The present raw data were analysed to assess the effect of Sac/Val-on cardiac remodeling and explore the mechanisms of Sac/Val-in protecting the myocardium in DCM rats. The data include the left ventricular/body mass index, IL-6 and TNF-α levels in myocardial tissue, the protein expression levels of phos-p38, Col Ⅰ and Col Ⅲ in myocardial tissue between pre- and post- Sac/Val-treatment in DCM rats. Compared to DCM rats, the degree of fibrosis and the protein expression of phos-p38, Col Ⅰ and Col Ⅲ reduced after the treatment of Sac/Val. These data may provide useful bases for future clinical research concerning the application of Sac/Val-in patients with DCM.

Keywords: Cardiac remodeling; Diabetic cardiomyopathy; Sacubitril/valsartan.